James Chih-Hsin Yang

James Chih-Hsin Yang

UNVERIFIED PROFILE

Are you James Chih-Hsin Yang?   Register this Author

Register author
James Chih-Hsin Yang

James Chih-Hsin Yang

Publications by authors named "James Chih-Hsin Yang"

Are you James Chih-Hsin Yang?   Register this Author

100Publications

4464Reads

31Profile Views

Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.

J Thorac Oncol 2019 Sep 23. Epub 2019 Sep 23.

Graduate Institute of Oncology, College of Medicine, National Taiwan University; Centers of Genomic and Precision Medicine, National Taiwan University; Department of Oncology, National Taiwan University Hospital, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.09.006DOI Listing
September 2019

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.

Eur J Cancer 2019 Aug 3;117:107-115. Epub 2019 Jul 3.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, ROC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.05.032DOI Listing
August 2019

Opportunities of circulating tumor DNA in lung cancer.

Cancer Treat Rev 2019 Aug 15;78:31-41. Epub 2019 Jul 15.

Department of Oncology, National Taiwan University Hospital, Taiwan; Graduate Institute of Oncology, National Taiwan University, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2019.07.002DOI Listing
August 2019

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

Lung Cancer 2019 Jul 17;133:103-109. Epub 2019 May 17.

Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.05.019DOI Listing
July 2019

Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Cancer Res Treat 2019 Jul 23. Epub 2019 Jul 23.

Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2019.200DOI Listing
July 2019

Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study.

Clin Lung Cancer 2019 Jul 10. Epub 2019 Jul 10.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2019.06.011DOI Listing
July 2019

Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit.

J Formos Med Assoc 2019 Jun 8;118(6):995-1004. Epub 2019 Mar 8.

Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan; Center of Sleep Disorder, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfma.2019.02.007DOI Listing
June 2019

Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?

Lancet Oncol 2019 May 8;20(5):602-603. Epub 2019 Apr 8.

Department of Oncology, National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University, Taipei 100, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30085-3DOI Listing
May 2019

First-line afatinib for the treatment of mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting.

Ther Adv Med Oncol 2019 15;11:1758835919836374. Epub 2019 Apr 15.

Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919836374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466470PMC
April 2019

Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.

J Formos Med Assoc 2019 Jan 27;118(1 Pt 2):230-236. Epub 2018 Apr 27.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfma.2018.04.001DOI Listing
January 2019

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.

J Thorac Oncol 2018 12 7;13(12):1897-1905. Epub 2018 Aug 7.

Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.07.093DOI Listing
December 2018

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 11 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2018 11 25;379(21):2027-2039. Epub 2018 Sep 25.

From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) - all in South Korea; National Taiwan University Hospital (J.C.-H.Y.) and the Faculty of Medicine, School of Medicine, National Yang-Ming University (G.-C.C.), Taipei, and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung (G.-C.C.) - all in Taiwan; the Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna (M.J.H.); Queen Elizabeth Hospital, Kowloon, Hong Kong (J.Y.-C.L.); Azienda Ospedaliera S. Giuseppe Moscati, Avellino (C.G.), the Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola (A.D.), Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS Struttura Operativa Complessa Oncologia Medica A, Aviano (A.B.), Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples (A.M.), and the Medical Oncology Unit, University Hospital of Parma, Parma (M.T.) - all in Italy; Complejo Hospitalario Universitario de A Coruña, Coruña (R.G.C.), and Vall d'Hebron University Hospital, Barcelona (E.F.) - both in Spain; the Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, Germany (F.G.); the Department of Medical Oncology, Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester (R.C.), and Guy's and St. Thomas' NHS Foundation Trust (S.G.) and Royal Marsden Hospital and the National Heart and Lung Institute, Imperial College London (S.P.), London - all in the United Kingdom; Virginia Cancer Specialists Research Institute and US Oncology Research, The Woodlands, TX (A.S.); Yale Cancer Center, New Haven, CT (S.N.G.); and Millennium Pharmaceuticals, Cambridge, MA (N.G., J.H., D.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1810171DOI Listing
November 2018

Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.

Genes Chromosomes Cancer 2018 10 14;57(10):513-521. Epub 2018 Aug 14.

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22647DOI Listing
October 2018

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply.

JAMA Oncol 2018 08;4(8):1138-1139

National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.1105DOI Listing
August 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

J Thorac Oncol 2018 06 23;13(6):792-800. Epub 2018 Mar 23.

Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.03.010DOI Listing
June 2018

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

Expert Opin Pharmacother 2018 06 22;19(8):851-864. Epub 2018 May 22.

a Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1472765DOI Listing
June 2018

Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.

Clin Lung Cancer 2018 05 1;19(3):e361-e372. Epub 2018 Feb 1.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.01.005DOI Listing
May 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 05 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Real-World or Controlled Clinical Trial Data in Real-World Practice.

J Thorac Oncol 2018 04;13(4):470-472

Department of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan (Republic of China); Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Republic of China; National Taiwan University Cancer Center, Taipei, Taiwan (Republic of China). Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.02.009DOI Listing
April 2018

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.

Lancet Respir Med 2018 02 14;6(2):107-116. Epub 2017 Dec 14.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22132600173048
Publisher Site
http://dx.doi.org/10.1016/S2213-2600(17)30480-0DOI Listing
February 2018

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2018 01 6;19(1):27-34. Epub 2017 Jul 6.

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.013DOI Listing
January 2018

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Nov 13;35(32):3662-3670. Epub 2017 Sep 13.

Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7297DOI Listing
November 2017

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial.

J Thorac Oncol 2017 10 24;12(10):1588-1594. Epub 2017 Jul 24.

Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.011DOI Listing
October 2017

Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.

Oncologist 2017 09 15;22(9):1075-1083. Epub 2017 May 15.

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0331DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599189PMC
September 2017

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Lung Cancer 2017 08 11;110:7-13. Epub 2017 May 11.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Cancer Center, College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.05.009DOI Listing
August 2017

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.

Clin Lung Cancer 2017 05 28;18(3):324-332.e1. Epub 2016 Dec 28.

Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.12.014DOI Listing
May 2017

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 04 19;12(4):633-643. Epub 2016 Dec 19.

National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; Cancer Care Centre, St. George Hospital, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.11.2236DOI Listing
April 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.

J Thorac Oncol 2017 03 5;12(3):567-572. Epub 2016 Dec 5.

Department of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Republic of China; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.11.2231DOI Listing
March 2017

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

J Thorac Oncol 2017 02 17;12(2):403-407. Epub 2016 Oct 17.

Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei City, Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.10.007DOI Listing
February 2017

Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al.

J Clin Oncol 2017 02 5;35(6):694-695. Epub 2016 Dec 5.

James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6978DOI Listing
February 2017

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.

Expert Rev Respir Med 2017 01 16;11(1):51-55. Epub 2016 Dec 16.

a Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2017.1267569DOI Listing
January 2017

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.

Curr Oncol Rep 2017 Jan;19(1)

Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-017-0560-2
Publisher Site
http://dx.doi.org/10.1007/s11912-017-0560-2DOI Listing
January 2017

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.

Expert Rev Mol Diagn 2016 12 27;16(12):1251-1257. Epub 2016 Oct 27.

a Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2016.1248414DOI Listing
December 2016

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 12 31;34(34):4079-4085. Epub 2016 Oct 31.

Shirish M. Gadgeel, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Alice T. Shaw, Massachusetts General Hospital; Leena Gandhi, Dana-Farber Cancer Institute, Boston, MA; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Mark A. Socinski, University of Pittsburgh, Pittsburgh, PA; D. Ross Camidge, University of Colorado Cancer Center, Denver, CO; Alberto Chiappori, Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Sai-Hong Ignatius Ou, University of California at Irvine, Orange, CA; Luigi De Petris, Karolinska Institutet, Stockholm, Sweden; Dong-Wan Kim, Seoul National University Hospital, Seoul; Ji-Youn Han, Lung Cancer Centre, National Cancer Centre, Goyang, South Korea; Denis L. Moro-Sibilot, Service de Pneumologie; Michael Duruisseaux, Centre Hospitalier Universitaire de Grenoble, Grenoble; Eric Dansin, Centre Oscar Lambret, Lille, France; Lucio Crino, Santa Maria della Misericordia Hospital, Perugia; Tommaso De Pas, European Institute of Oncology, Milan, Italy; Antje Tessmer, Evangelische Lungenklinik Berlin, Berlin, Germany; James Chih-Hsin Yang, Graduate Institute of Oncology and Cancer Research Centre, National Taiwan University, Taipei, Taiwan; and Walter Bordogna, Sophie Golding, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.4639DOI Listing
December 2016

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.

J Biomed Sci 2016 Dec 3;23(1):86. Epub 2016 Dec 3.

Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, 100, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12929-016-0305-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135794PMC
December 2016

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2016 10 27;34(28):3375-82. Epub 2016 Jun 27.

Geoffrey R. Oxnard, Ryan S. Alden, Cloud P. Paweletz, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston; Kenneth S. Thress and J. Carl Barrett, AstraZeneca, Waltham, MA; Rachael Lawrance and Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; and James Chih-Hsin Yang, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035123PMC
http://dx.doi.org/10.1200/JCO.2016.66.7162DOI Listing
October 2016

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.

Clin Lung Cancer 2016 09 30;17(5):e77-e94. Epub 2016 Mar 30.

Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.03.005DOI Listing
September 2016

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Clin Lung Cancer 2016 09 29;17(5):e103-e112. Epub 2016 Apr 29.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.04.003DOI Listing
September 2016

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

J Clin Oncol 2016 09 9;34(27):3258-66. Epub 2016 Aug 9.

Ying Cheng, Jilin Provincial Cancer Hospital, Changchun; Jianxing He, The First Affiliated Hospital of Guangzhou Medical University, Guangdong; Xin Wang, Eli Lilly, Shanghai, China; Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka; Kazuhiko Nakagawa, Kinki University School of Medicine, Osaka; Sotaro Enatsu, Eli Lilly Japan, Kobe, Japan; Pan-Chyr Yang and James Chih-Hsin Yang, National Taiwan University Hospital; James Chih-Hsin Yang, National Taiwan University Cancer Center, Taipei, Taiwan; Jin Hyoung Kang, The Catholic University of Korea, Seoul; Joo-Hang Kim, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; and Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9218DOI Listing
September 2016

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer.

Case Rep Oncol 2016 May-Aug;9(2):474-480. Epub 2016 Aug 17.

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000448804DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043363PMC
August 2016

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.

J Thorac Oncol 2016 07 16;11(7):1140-52. Epub 2016 Apr 16.

Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 10002, Republic of China; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.03.022DOI Listing
July 2016

Safety of gefitinib in non-small cell lung cancer treatment.

Expert Opin Drug Saf 2016 Jul 7;15(7):993-1000. Epub 2016 Jun 7.

a Department of Oncology , National Taiwan University Hospital , Taipei , Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2016.1192605DOI Listing
July 2016

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice.

J Cancer 2016 7;7(11):1515-23. Epub 2016 Jul 7.

7. Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; 8. Taiwan Cancer Registry, Department of Internal Medicine, E-Da Hospital, Kaohsiung, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/jca.15180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964135PMC
July 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

J Clin Oncol 2016 Mar 23;34(7):661-8. Epub 2015 Nov 23.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA; Jin Seok Ahn, Sungkyunkwan University School of Medicine; Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan; Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia; Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes; Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France; Alessandra Bearz, National Cancer Institute, Aviano, Italy; Santiago Viteri Ramirez, Quiron-Dexeus University Hospital, Barcelona, Spain; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; and Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/jco.2016.34.4_suppl.661DOI Listing
March 2016

Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.

PLoS One 2015 25;10(3):e0119135. Epub 2015 Mar 25.

National Center of Excellence for Clinical Trial and Research, National Taiwan University, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan; Graduate Institute of Oncology, National Taiwan University and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119135PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373825PMC
February 2016

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.

J Thorac Oncol 2015 Dec;10(12):1754-61

*Department of Oncology, †Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan; ‡Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan; §Department of Medical Imaging, ‖Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; and ¶Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000669DOI Listing
December 2015

The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia.

Oncologist 2015 Sep 3;20(9):1051-7. Epub 2015 Aug 3.

Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China; Departments of Oncology, Internal Medicine, and Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China; Graduate Institute of Oncology, College of Medicine, and Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, Republic of China; Center for Comparative Effectiveness Research, National Center of Excellence for Clinical Trial and Research, Taipei, Taiwan, Republic of China; Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan, Republic of China; Taiwan Cancer Registry, Taipei, Taiwan, Republic of China

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571799PMC
September 2015

Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.

J Thorac Oncol 2015 Sep;10(9):e95-e96

Graduate Institute of Oncology, National Taiwan University and, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000611DOI Listing
September 2015

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Ther Adv Med Oncol 2015 Sep;7(5):274-90

Department of Oncology, National Taiwan University Hospital, Taiwan Graduate Institute of Oncology and Cancer Research Center, College of Medicine, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834015590593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543853PMC
September 2015

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

J Clin Oncol 2015 Jun 20;33(17):1958-65. Epub 2015 Apr 20.

Chee Khoon Lee, Pei Ni Ding, Sarah J. Lord, and Val Gebski, National Health and Medical Research Council Clinical Trials Centre, The University of Sydney; Chee Khoon Lee and Matthew Links, Cancer Care Centre, St George Hospital; Pei Ni Ding, Liverpool Hospital; Sarah J. Lord, School of Medicine, The University of Notre Dame; Nick Pavlakis, Royal North Shore Hospital, Sydney, Australia; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangdong; Caicun Zhou, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China; Akira Inoue, Tohoku University Hospital, Sendai; Tetsuya Mitsudomi, Kinki University School of Medicine, Osaka-Sayama, Japan; Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain; Richard J. Gralla, Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY; James Chih-Hsin Yang, Graduate Institute of Oncology, National Taiwan University, and National Taiwan University Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.1736
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.1736DOI Listing
June 2015

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.

J Thorac Oncol 2015 May;10(5):793-9

*Department of Chest Medicine, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan; †Department of Thoracic Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; ‡Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan §Department of Internal Medicine, Kaohsiung Medical University Hospital and Kaohsiung Medical University, Kaohsiung, Taiwan; ‖Department of Internal Medicine, National Cheng Kung University Hospital and National Cheng Kung University, Tainan, Taiwan; ¶Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; #Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; **Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; ††Department of Pulmonary and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi and Chang Gung University, Taoyuan, Taiwan; ‡‡department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan; §§Department of Respiratory Therapy, China Medical University Hospital and China Medical University, Taichung, Taiwan; ‖‖School of Medicine, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan; ¶¶Department of Internal Medicine, Buddhist Dalin Tzu Chi Hospital, Chiayi and Tzu Chi University, Hualien, Taiwan; ##Department of Pulmonary Medicine, Shuang Ho Hospital and Taipei Medical University, Taipei, Taiwan; ***Department of Internal Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan; †††Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan; and; ‡‡‡Department of Internal Medicine, Ren-ai Branch, and §§§Department of Internal Medicine, Zhong-xiao Branch, Taipei City Hospital, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000504DOI Listing
May 2015

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.

Lung Cancer 2015 May 4;88(2):208-14. Epub 2015 Mar 4.

Department of Internal Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.02.018DOI Listing
May 2015

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.

Oncotarget 2015 Apr;6(12):10415-31

Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496364PMC
http://dx.doi.org/10.18632/oncotarget.3389DOI Listing
April 2015

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

N Engl J Med 2015 Apr;372(18):1689-99

From the Lowe Center for Thoracic Oncology and the Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston (P.A.J.); National Taiwan University and National Taiwan University Hospital (J.C.-H.Y.) and Cheng Kung University Hospital (W.-C.S.) - both in Taipei, Taiwan; Seoul National University Hospital (D.-W.K.), Samsung Medical Center (M.-J.A.), Asan Medical Center (S.-W.K.), and Yonsei Cancer Center, Yonsei University Health System (J.-H.K.) - all in Seoul, South Korea; Institut Gustave Roussy, Villejuif, France (D.P.); National Cancer Center Hospital, Tokyo (Y.O.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); Vanderbilt Ingram Cancer Center, Nashville (L.H.); Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC (D.H.); Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona (E.F.); and AstraZeneca, Macclesfield (P.F., M.C., K.H.B., P.A.D., S.G.), and University of Manchester, Christie Hospital, Manchester (M.R.) - both in the United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1411817DOI Listing
April 2015